SCHEMBL11030745

SCHEMBL11030745

CN1CCN(c2ccc(Nc3cc(C(C)(C)c4cccc(F)c4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 3/20 0.50
▸ CCND1 P24385 2/20 0.50
▸ SLC2A1 P11166 2/20 0.47
▸ MAPKAPK2 P49137 2/20 0.45
▸ EGFR P00533 1/20 0.45
▸ FYN P06241 1/20 0.44
▸ PTK2 Q05397 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ BRD4 O60885 3/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ AURKA O14965 2/20 0.43
▸ CDK2 P24941 2/20 0.43
▸ FGFR4 P22455 1/20 0.43
▸ LCK P06239 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ CDK6 Q00534 2/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CCND3 P30281 1/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ CCNT1 O60563 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11026741 0.85 FYN (0.55) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11028029 0.81 CDK4 (0.53) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11028698 0.81 CDK4 (0.51) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11033766 0.79 SLC2A1 (0.51) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11029599 0.78 MAPKAPK2 (0.58) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11029346 0.78 MAPKAPK2 (0.61) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11031445 0.78 SLC2A1 (0.51) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11029790 0.77 MAPKAPK2 (0.52) SLC2A1MAPKAPK2EGFRFYNPTK2
SCHEMBL11031861 0.77 SLC2A1 (0.55) CDK4CCND1SLC2A1MAPKAPK2EGFR
SCHEMBL11027433 0.77 MAPKAPK2 (0.60) CDK4CCND1SLC2A1MAPKAPK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 CDK4 78/4885CCND1 547/4885SLC2A1 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback